Trial Profile

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGEN 2373 (Primary) ; Botensilimab (Primary)
Indications Carcinoma; Malignant melanoma; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Agenus

Most Recent Events

13 Jan 2025 Status changed from active, no longer recruiting to completed.
29 Mar 2024 Status changed from recruiting to active, no longer recruiting.
06 Jun 2023 Results (n=46; enrolled between Oct 2019 and May 2022) assessing the safety, pharmacokinetics and efficacy of AGEN2373 in patients with advanced solid tumors, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com